Summit Therapeutics SMMT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Summit Therapeutics (SMMT) reported accretion (amortization) of discounts and premiums, investments of $4.22M in Q1 2026.
- How has Summit Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Summit Therapeutics's accretion (amortization) of discounts and premiums, investments increased by 42.2% year-over-year, from $2.97M to $4.22M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Non-cash adjustments to the value of investment holdings over time.
- How do you interpret accretion (amortization) of discounts and premiums, investments?
- Fluctuations reflect changes in the company's investment portfolio strategy and interest rate environment.
- How does accretion (amortization) of discounts and premiums, investments compare across companies?
- Standard for companies holding significant cash equivalents or marketable securities.